Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways
Journal of Pharmacy and Pharmacology · 2023
DOI: 10.1093/jpp/rgad070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Xiangfeng Zeng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. Hauptthemen laut MEDLINE: Ginsenosides, Lung Neoplasms, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
The most common cause of osteosarcoma (OS) death is lung metastasis. Currently, doxorubicin is the primary chemotherapy drug used to treat OS, however, it is not effective in inhibiting metastasis, and it has obvious cardiotoxicity. The anticancer activity of ginsenoside Rg3 has been demonstrated in a variety of malignant tumours. The aim of this study was to determine the potential role of ginsenoside Rg3 and doxorubicin in OS and the possible mechanism.
Methods
The potential synergistic effects of ginsenoside Rg3 and doxorubicin on human osteosarcoma cells 143B and U2OS, human umbilical vein endothelial cells, and mice receiving 143B xenografts and lung metastases were investigated. Key findings Our study demonstrated that the combination of ginsenoside Rg3 and doxorubicin significantly inhibited cell proliferation, metastasis and angiogenesis in vitro. Mechanically, the anti-tumour activity of ginsenoside Rg3 and doxorubicin by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways. Furthermore, ginsenoside Rg3 combined with doxorubicin inhibits tumour growth and lung metastasis in 143B-derived murine osteosarcoma models. More importantly, ginsenoside Rg3 can effectively ameliorate doxorubicin-induced weight loss and cardiotoxicity in mice.
Conclusions
Consequently, we concluded that the combination of ginsenoside Rg3 and doxorubicin displayed an evidently synergistic effect, which has the potential to be used as an effective and safe therapeutic approach for OS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- Department of Orthopedics, Changde Hospital, Xiangya School of Medicine, Central South University, Changde, Hunan, China.
- Department of Orthopedics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Pharmacy, Biomedicine Research Center, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hos…
ORCID-Profile: Wenting Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zeng, X., Liu, S., Yang, H., Jia, M., Liu, W., & Zhu, W. (2023). Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad070
Vancouver
Zeng X, Liu S, Yang H, Jia M, Liu W, Zhu W. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad070
BibTeX
@article{Zeng2023,
author = {Zeng, Xiangfeng and Liu, Shengyao and Yang, Hua and Jia, Menglei and Liu, Wei and Zhu, Wenting},
title = {Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
doi = {10.1093/jpp/rgad070}
}
EUVIMED